Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts payable Accounts Payable, Trade, Current Accrued payroll and related costs Employee-related Liabilities, Current Accrued clinical trial expense Accrued Clinical Trial Expense Current Carrying value as of the balance sheet date of obligations incurred (and for which invoices have not been received) in connection with clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued sales-related deductions and royalties Accrued sales related deductions and royalties Carrying value as of the balance sheet date of sales-related deductions and obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Other accrued expenses and liabilities Other Accrued Liabilities, Current Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Class A Stock Common Class A [Member] Statement [Line Items] Liabilities and Equity [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common Stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Common Stock, shares issued (in shares) Common Stock, Shares, Issued Common Stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Statement of Cash Flows [Abstract] Statement [Table] Statement, Scenario [Axis] Statement, Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Adjustments to reconcile net income (loss) to net cash used in by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Non-cash compensation expense Share-based Compensation Other non-cash charges and expenses, net Other Noncash Income (Expense) Changes in assets and liabilites Increase (Decrease) in Operating Capital [Abstract] (Increase) decrease in Sanofi and trade accounts receivable Increase (Decrease) in Accounts Receivable (Increase) decrease in prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Decrease in deferred revenue Increase (Decrease) in Deferred Revenue Increase in accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Total adjustments Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Marketable Securities Sales or maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Increase in restricted cash and marketable securities Increase (Decrease) in Restricted Cash and Investments Capital expenditures Payments to Acquire Productive Assets Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Payments in connection with facility and capital lease obligations Repayments of Long-term Capital Lease Obligations Net proceeds from issuances of Common Stock Proceeds from Issuance of Common Stock Payments in connection with Common Stock tendered for employee tax obligations Payments Related to Tax Withholding for Share-based Compensation Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Investments, Debt and Equity Securities [Abstract] Marketable Securities Marketable Securities [Text Block] Loss Contingency, Information about Litigation Matters [Abstract] Legal Matters Legal Costs, Policy [Policy Text Block] Fair Value Disclosures [Abstract] Schedule of assets measured at fair value on a recurring basis Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Revenues [Abstract] Revenue Disclosure [Table] Revenue Disclosure [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] EYLEA EYLEA Net Product Sales [Member] Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions. ARCALYST Arcalyst Net Product Sales [Member] Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions. ZALTRAP ZALTRAP [Member] ZALTRAP [Member] Concentration Risk by Type [Axis] Concentration Risk Type [Domain] Customer concentration risk Customer Concentration Risk [Member] Concentration Risk by Benchmark [Axis] Concentration Risk by Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Gross Sales Revenue GrossSalesRevenue [Member] GrossSalesRevenue [Member] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Rebates and Chargebacks Rebates and Chargebacks [Member] A valuation allowance for rebates and chargebacks under governmental programs (including Medicaid), which are netted against revenue from product sales. Distribution Related Fees Distribution Related Fees [Member] A valuation allowance for distribution-related fees which are netted against revenue from product sales. Other Sales Related Deductions Other Sales Related Deductions [Member] A valuation allowance for other sales-related deductions which are netted against revenue from product sales. Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaboration Agreement with Sanofi Collaboration Agreement with Sanofi [Member] Collaboration agreement with Sanofi. Collaboration Agreement with Bayer HealthCare LLC Collaboration Agreement with Bayer HealthCare LLC [Member] Collaboration agreement with Bayer HealthCare LLC. Revenue Disclosure [Line Items] Revenue Disclosure [Line Items] Revenue Disclosure [Line Items] Substantive milestone payment Revenue Recognition, Milestone Method, Revenue Recognized Net Product Sales [Abstract] Sales Revenue, Goods, Net [Abstract] Net product sales Sales Revenue, Goods, Net Net profit (loss) from commercialization of products under collaboration agreement Income (Loss) From Products Commercialized by our Collaboration Partner Our share of profits/losses related to commercialization of products by our collaborator. Under the terms of our collaboration agreement, we share profits/losses with our collaborator on commercialization of products outside of Japan, and we are entitled to a royalty of approximately 35% on annual product sales in Japan, subject to certain potential adjustments. Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Concentration risk, percentage Entity Wide Revenue Major Customer Percentage Percentage of revenue generated from a single external customer that accounts for 10 percent or more of an entity's revenues. Activity of Sales Related Deductions [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance as of December 31, 2011 Valuation Allowances and Reserves, Balance Provision related to current period sales Valuation Allowances and Reserves, Charged to Other Accounts Credits/payments Valuation Allowances and Reserves, Deductions Balance as of September 30, 2012 Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Statement of Cash Flows Cash Flow, Supplemental Disclosures [Text Block] Commitments and Contingencies Disclosure [Abstract] Legal Matters Legal Matters and Contingencies [Text Block] Statement of Stockholders' Equity [Abstract] Statement, Equity Components [Axis] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Member] Increase (decrease) in stockholders' equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, shares Shares, Outstanding Balance Stockholders' Equity Attributable to Parent Issuance of Common Stock in connection with exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of Common Stock in connection with exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Common Stock tendered upon exercise of stock options in connection with employee tax obligations (in shares) Shares Paid for Tax Withholding for Share Based Compensation Common Stock tendered upon exercise of stock options in connection with employee tax obligations Adjustments Related to Tax Withholding for Share-based Compensation Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution Stock Issued During Period, Value, Employee Benefit Plan Issuance of restricted Common Stock under Long-Term Incentive Plan (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of restricted Common Stock under Long-Term Incentive Plan Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Conversion of Class A Stock to Common Stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of Class A Stock to Common Stock Stock Issued During Period, Value, Conversion of Convertible Securities Stock-based compensation charges Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Balance, shares Balance New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Recently Issued Accounting Standards New Accounting Pronouncements and Changes in Accounting Principles [Text Block] The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Marketable securities Marketable Securities, Current Accounts receivable - trade, net Accounts Receivable, Net, Current Accounts receivable from Sanofi Due from Related Parties, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Restricted cash and marketable securities Restricted Cash and Investments, Noncurrent Marketable securities Marketable Securities, Noncurrent Property, plant, and equipment, at cost, net of accumulated depreciation and amortization Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES and STOCKHOLDERS' EQUITY Current liabilities: Liabilities, Current [Abstract] Accounts payable and accrued expenses Deferred revenue from Sanofi, current portion Deferred Revenue From Related Party Current The current portion of deferred revenue from related parties as of balance sheet date. Current deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Deferred Revenue, Current Deferred Revenue, Current Facility lease obligations, current portion Facility Lease Obligations, Current Represents the current portion of a lease liability. In connection with the application of FASB authoritative guidance to the Company's lease of additional new facilities, the Company is deemed, in substance, to be the owner of the landlord's building; therefore, costs of constructing the facilities that the Company incurred and reimbursements from the Company's landlord for tenant improvement costs were capitalized, offset by a corresponding lease obligation. Total current liabilities Liabilities, Current Deferred revenue from Sanofi Deferred Revenue From Related Party Noncurrent The noncurrent portion of deferred revenue from related parties amount as of balance sheet date. Noncurrent deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Deferred Revenue, Noncurrent Deferred Revenue, Noncurrent Facility lease obligations Facility lease obligations noncurrent Represents the noncurrent portion of a lease liability. In connection with the application of FASB authoritative guidance to the Company's lease of additional new facilities, the Company is deemed, in substance, to be the owner of the landlord's building; therefore, costs of constructing the facilities that the Company incurred and reimbursements from the Company's landlord for tenant improvement costs were capitalized, offset by a corresponding lease obligation. Convertible senior notes Convertible Notes Payable, Noncurrent Other long term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and Contingencies Preferred stock Preferred Stock, Value, Issued Common Stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value by Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Measured on a recurring basis Fair Value, Measurements, Recurring [Member] Classification of Investment [Axis] This element represents the general categories of investments, which may be classified as Unrestricted or Restricted. Classification of Investment [Domain] Provides general categories of investments for which information is required or determined to be disclosed. Unrestricted Unrestricted [Member] Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements. Restricted Restricted [Member] Investments whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Estimate of Fair Value, Fair Value Disclosure [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Number of marketable securities held Number Of Marketable Securities Held Disclosure of the number of marketable securities held as of the reporting date. Available-for-sale marketable securities: Available-for-sale Securities [Abstract] U.S. government obligations U S Government Obligations Fair Value Disclosure This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. This item represents available-for-sale securities which consist of investments in U.S. government obligations neither classified as trading or held-to-maturity securities. U.S. government guaranteed corporate bonds U S Government Guaranteed Corporate Bonds Fair Value Disclosure This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. This item represents available-for-sale securities which consist of investments in U.S. government guaranteed corporate bonds neither classified as trading or held-to-maturity securities. U S government guaranteed collateralized mortgage obligations U S Government Guaranteed Collateralized Mortgage Obligations Fair Value Disclosure This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. This item represents available-for-sale securities which consist of investments in U.S. government guaranteed collateralized mortgage obligations neither classified as trading or held-to-maturity securities. Municipal bonds Municipal bonds fair value disclosure This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. This item represents available-for-sale securities which consist of investments in municipal bonds neither classified as trading or held-to-maturity securities. Mortgage-backed securities Mortgage backed securities fair value disclosure This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. This item represents available-for-sale securities which consist of investments in mortgage-backed securities neither classified as trading or held-to-maturity securities. Equity security Equity security fair value disclosure This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. This item represents available-for-sale securities which consist of investments in equity securities neither classified as trading or held-to-maturity securities. Total fair value of available-for-sale marketable securities Available-for-sale Securities, Fair Value Disclosure Convertible Debt [Abstract] Convertible Debt [Abstract] Principal amount Debt Instrument, Face Amount Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Fair value of the outstanding notes Convertible Debt, Fair Value Disclosures Inventory Disclosure [Abstract] Raw materials Inventory, Raw Materials Work in process Inventory, Work in Process Finished goods Inventory, Finished Goods Total Inventories Inventory, Net Inventories included in other assets Inventory, Noncurrent Inventory write down and reserves Inventory Write-down Fair Value Measurements Fair Value Disclosures [Text Block] Revenue Recognition, Product Revenue Revenue Recognition, Sales of Goods [Policy Text Block] Revenue Recognition, Revenue Reductions Revenue Recognition, Revenue Reductions [Policy Text Block] Earnings Per Share [Abstract] Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Loss Contingencies [Table] Loss Contingencies by Nature of Contingency [Axis] Loss Contingency, Nature [Domain] Genentech patent-related matters Pending or Threatened Litigation [Member] License agreement with Genentech License Agreement With Genentech [Member] A non-exclusive license agreement with Genentech which requires the Company to make certain payments if certain sales targets are exceeded during the term of the agreement. Loss Contingencies by Geographic Area [Axis] Geographic area of each loss contingency that exists as of the balance sheet date. Loss Contingencies by geographic area [Domain] Identification of the geographic area of each loss contingency that exists as of the balance sheet date. United States UNITED STATES Europe Europe [Member] The geographic area of Europe. Loss Contingencies [Line Items] Number of patent litigations Loss Contingency, Pending Claims, Number Amount of payment to be made upon reaching minimum sales target Amount of payment made upon reaching minimum sales target The amount of payment made by the Company upon cumulative U.S. sales of EYLEA reaching a minimum sales target, under the terms of the non-exclusive license agreement. Cumulative sales range, minimum Cumulative Sales Range Minimum The minimum amount of cumulative U.S. sales of EYLEA which would require the Company to make payments. Royalty payment percentage of cumulative sales within cumulative sales range Royalty Payment Percentage Of Cumulative Sales Within Range Royalty payment percentage to be made on cumulative U.S. sales of EYLEA within the cumulative sales range, under the terms of the non-exclusive license agreement. Cumulative sales range, maximum Cumulative Sales Range Maximum The maximum amount of cumulative U.S. sales of EYLEA within the range, which will require the Company to make royalty payments of 4.75%. Royalty payment percentage of cumulative sales over range Royalty Payment Percentage Of Cumulative Sales Over Range Percentage of royalty payment to be made on cumulative U.S. sales of EYLEA over the cumulative sales range, under the terms of the non-exclusive license agreement. Accounts Payable and Accrued Expenses Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Document And Entity Information [Abstract] -- None. No documentation exists for this element. -- Entities [Table] Entity Information [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Public Float Entity Public Float Interim Financial Statements [Abstract] -- None. No documentation exists for this element. -- Interim Financial Statements Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Sales Related Deductions Activity Schedule of Sales Related Deductions Activity [Table Text Block] Tabular disclosure of the activity of sales-related deductions during the period, which may include rebates and chargebacks, and distributor-related fees. Marketable Securities, Based on Contractual Maturity Dates Investments Classified by Contractual Maturity Date [Table Text Block] Fair Value and Unrealized Losses of Marketable Securities Schedule of Unrealized Loss on Investments [Table Text Block] Inventory Inventory Disclosure [Text Block] Per Share Data Earnings Per Share [Text Block] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Change in unrealized gain (loss) on marketable securities, income tax expense (benefit) Available-for-sale Securities, Income Tax Expense on Change in Unrealized Holding Gain (Loss) Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Convertible senior notes - interest expense related to contractual coupon interest rate and amortization of discount and note issuance costs Interest on Convertible Debt, Net of Tax Net income (loss) - diluted Net Income (Loss) Available to Common Stockholders, Diluted Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted average shares - basic Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities (in shares): Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract] Stock options Incremental Common Shares Attributable to Share-based Payment Arrangements Restricted stock Incremental Common Shares Attributable To Nonvested Restricted Shares Nonvested equity-based payment awards that result in incremental common shares. Convertible senior notes Incremental Common Shares Attributable to Conversion of Debt Securities Warrants Incremental Common Shares Attributable to Call Options and Warrants Dilutive potential shares Weighted Average Number Diluted Shares Outstanding Adjustment Weighted average shares - diluted Weighted Average Number of Shares Outstanding, Diluted Earnings Per Share, Basic and Diluted [Abstract] Net income (loss) per share - basic Earnings Per Share, Basic Net income (loss) per share - diluted Earnings Per Share, Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Stock options Stock Options [Member] Restricted stock Restricted Stock [Member] Convertible senior notes Convertible Debt Securities [Member] Warrants Warrants [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted average number of shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue Revenue And Concentration Risk Disclosure [Text Block] Revenue And Concentration Risk Disclosure [Text Block] Accrued capital expenditures Accrued Capital Expenditures Carrying value as of the balance sheet date of obligations incurred and payable for purchases of fixed assets. Included in accounts payable and accrued expenses. Non-cash charges of fixed assets disposals and retirements Impairment of Long-Lived Assets to be Disposed of Accrued interest income Accrued Investment Income Receivable Statement of Income and Comprehensive Income [Abstract] Income Statement [Abstract] Income Statement [Abstract] Revenues: Sanofi collaboration revenue Related Party Transaction, Revenues from Transactions with Related Party Bayer HealthCare collaboration revenue Other Collaboration Revenue Revenue realized from sharing of profits/losses on commercialized products, cost sharing of development expenses, and other transactions with our collaborator Bayer HealthCare during the period. Technology licensing Licenses Revenue Contract research and other Contracts Revenue Total revenues Revenues Expenses: Costs and Expenses [Abstract] Research and development Research and Development Expense Selling, general, and administrative Selling, General and Administrative Expense Cost of goods sold Cost of Goods Sold Total expenses Costs and Expenses Income (loss) from operations Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Investment income Investment Income, Nonoperating Interest expense Interest Expense Total other income (expense) Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income tax (expense) benefit Income Tax Expense (Benefit) Net income (loss) Weighted average shares outstanding - basic Weighted average shares outstanding - diluted Condensed Statements of Comprehensive Income (Loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Unrealized gain (loss) on marketable securities, net of tax Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Equity securities Equity Securities [Member] Debt securities Debt Securities [Member] U.S. government obligations US Treasury and Government [Member] U.S. government guaranteed corporate bonds U S Government Guaranteed Corporate Bonds [Member] This category includes investments in debt securities issued by corporations that are guaranteed by the U.S. Government. Municipal bonds US States and Political Subdivisions Debt Securities [Member] Mortgage-backed securities Mortgage-backed Securities, Issued by Private Enterprises [Member] U.S. government guaranteed collateralized mortgage obligations Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member] Schedule of Available-for-sale Securities [Line Items] Fair value of equity securities Available-for-sale Securities, Equity Securities Cost basis of equity securities Available-for-sale Equity Securities, Amortized Cost Basis Debt Maturities, Amortized Cost Basis [Abstract] Available-for-sale Securities, Debt Maturities, Amortized Cost Basis [Abstract] Amortized Cost Basis - Maturities within one year Available-for-sale Securities, Debt Maturities, within One Year, Amortized Cost Basis Amortized Cost Basis - Maturities after one year through five years Available-for-sale Securities, Debt Maturities, after One Through Five Years, Amortized Cost Basis Amortized Cost Basis - Maturities after five years through ten years Available-for-sale Securities, Debt Maturities, after Five Through Ten Years, Amortized Cost Basis Amortized Cost Basis - Total Available-for-sale Securities, Debt Maturities, Amortized Cost Basis Unrealized Gains (Losses), Net [Abstract] Available-for-sale Securities, Gross Unrealized Gain (Loss) [Abstract] Unrealized Gains - Maturities within one year Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature within one year of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Maturities after one year through five years Available For Sale Securities Debt Maturities After One Through Five Years Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature after one year and through five years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Maturities after five years through ten years Available For Sale Securities Debt Maturities After Five Through Ten Years Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature after five years and through ten years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Total Available-for-sale Securities, Gross Unrealized Gains Unrealized (Losses) - Maturities within one year Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Loss This item represents the gross unrealized losses of debt securities which are expected to mature within one year of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Maturities after one year through five years Available For Sale Securities Debt Maturities After One Through Five Years Gross Unrealized Loss This item represents the gross unrealized losses of debt securities which are expected to mature after one year and through five years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Maturities after five years through ten years Available For Sale Securities Debt Maturities After Five Through Ten Years Gross Unrealized Loss This item represents the gross unrealized losses of debt securities which are expected to mature after five years and through ten years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Total Available-for-sale Securities, Gross Unrealized Losses Debt Maturities, Fair Value [Abstract] Available-for-sale Securities, Debt Maturities, Fair Value [Abstract] Fair Value - Maturities within one year Available-for-sale Securities, Debt Maturities, within One Year, Fair Value Fair Value - Maturities after one year through five years Available-for-sale Securities, Debt Maturities, after One Through Five Years, Fair Value Fair Value - Maturities after five years through ten years Available-for-sale Securities, Debt Maturities, after Five Through Ten Years, Fair Value Fair Value - Total Available-for-sale Securities, Debt Securities Continuous Unrealized Loss Position, Fair Value [Abstract] Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract] Fair Value - Less than 12 Months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Fair Value - 12 Months or Greater Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Fair Value - Total Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Continuous Unrealized Loss Position, Aggregate Losses [Abstract] Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses [Abstract] Unrealized Loss - Less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses Unrealized Loss - 12 Months or Greater Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses Unrealized Loss - Total Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses Available-for-sale Securities, Gross Realized Gains Available-for-sale Securities, Gross Realized Losses